- Home
- LIN vs GILD Comparison
LIN vs GILD Comparison
Compare LIN & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIN | GILD |
|---|---|---|
| Founded | 1879 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.1B | 187.4B |
| IPO Year | 2017 | 2003 |
Fundamental Metrics
Financial Performance| Metric | LIN | GILD |
|---|---|---|
| Price | $492.64 | $153.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 28 |
| Target Price | ★ $544.30 | $159.62 |
| AVG Volume (30 Days) | 1.9M | ★ 5.2M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | 1.30% | ★ 2.22% |
| EPS Growth | 7.27 | ★ 1684.21 |
| EPS | ★ 8.13 | N/A |
| Revenue | ★ $33,986,000,000.00 | $24,689,000,000.00 |
| Revenue This Year | $6.92 | $4.39 |
| Revenue Next Year | $4.87 | $6.76 |
| P/E Ratio | $60.53 | ★ N/A |
| Revenue Growth | 2.97 | ★ 9.98 |
| 52 Week Low | $387.78 | $114.02 |
| 52 Week High | $548.20 | $157.29 |
Technical Indicators
Market Signals| Indicator | LIN | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 60.92 |
| Support Level | $487.51 | $142.91 |
| Resistance Level | $497.42 | $157.29 |
| Average True Range (ATR) | 6.91 | 3.31 |
| MACD | 2.64 | 0.09 |
| Stochastic Oscillator | 95.01 | 97.31 |
Price Performance
Historical ComparisonAbout LIN Linde plc
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $34 billion in revenue in 2025.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).